FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
Highlights: FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol This marks the official entry of NUZ-001 as Regimen I in the HEALEY ALS Platform Trial Next steps include obtaining single...
NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease
Highlights: NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington's disease Treatment prevented hallmark developmental and morphological abnormalities, protected against...
Neurizon Files IND Application to Support HEALEY ALS Platform Trial
Highlights: IND application submission to the U.S. Food and Drug Administration (FDA) is a pivotal step in initiating a Phase 2/3 clinical study for NUZ-001 The IND is a comprehensive dossier of information, including animal and human studies,...